Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487265 | 0.92 | NR3C1 (0.41) | NR3C1PGRNR3C2AR | |
| SCHEMBL4477332 | 0.88 | NR3C1 (0.36) | NR3C1PGRNR3C2ARESR1 | |
| SCHEMBL4484191 | 0.85 | NR3C1 (0.37) | NR3C1PGRNR3C2ARESR1 | |
| SCHEMBL1120907 | 0.83 | ESR1 (0.41) | NR3C1ESR1ESR2 | |
| SCHEMBL1120902 | 0.81 | NR3C1 (0.42) | NR3C1PGRNR3C2AR | |
| SCHEMBL4484186 | 0.81 | NR3C1 (0.42) | NR3C1PGRNR3C2AR | |
| SCHEMBL1120793 | 0.79 | NR3C1 (0.39) | NR3C1PGRNR3C2AR | |
| SCHEMBL1120832 | 0.78 | MCL1 (0.40) | NR3C1 | |
| SCHEMBL1120786 | 0.75 | NR3C1 (0.45) | NR3C1PGRNR3C2AR | |
| SCHEMBL4513399 | 0.75 | ADRB3 (0.57) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | claimed |
| US-7598284-B2 | Indazole compounds as B3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-10-06 | — | — | US | disclosed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7271190-B2 | Indazole compounds as β3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020602-A1 | Bicyclic compound | GOT1, H1-0, HSD11B1 | NR3C1 498/4885PGR 2007/4885NR3C2 322/4885 |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | OPRL1, NPBWR1, NPY4R | NR3C1 230/4885PGR 885/4885NR3C2 122/4885 |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | NR3C1 301/4885PGR 1513/4885NR3C2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.